Home » Stocks » Immunovant

Immunovant, Inc. (IMVT)

Stock Price: $23.67 USD 0.22 (0.94%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.56B
Revenue (ttm) n/a
Net Income (ttm) -66.39M
Shares Out 74.27M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $23.67
Previous Close $23.45
Change ($) 0.22
Change (%) 0.94%
Day's Open 23.77
Day's Range 23.24 - 24.38
Day's Volume 344,470
52-Week Range 8.34 - 29.96

More Stats

Market Cap 1.56B
Enterprise Value 1.46B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 74.27M
Float 8.28M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -1.24
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 438,254
Short Ratio 1.09
Short % of Float 0.61%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 16.62
Revenue n/a
Operating Income -66.08M
Net Income -66.39M
Free Cash Flow -53.39M
Net Cash 100.57M
Net Cash / Share 1.52
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC -123.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(35.19% upside)
Current: 23.67
Target: 32.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-66.08-28.43
Net Income-66.39-28.60
Shares Outstanding43.2022.17
Earnings Per Share-1.54-1.29
Operating Cash Flow-53.36-28.55
Capital Expenditures-0.03-0.05
Free Cash Flow-53.39-28.60
Cash & Equivalents1016.99
Net Cash / Debt1016.99
Book Value94.077.34
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Immunovant, Inc.
Country United States
Employees 18
CEO Peter Salzmann

Stock Information

Ticker Symbol IMVT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMVT


Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.